

Talking Biotech with Dr. Kevin Folta
Colabra
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering.
Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.
Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.
Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
Episodes
Mentioned books

Dec 27, 2025 • 1h 12min
TB Throwback- Correcting the Veritasium Episode on Glyphosate
This is a throwback to episode 484, a very important correction of their episode on glyphosate. With so much controversy around this compound it is critical to keep the information correct and consistent with a 50 year body of evidence when discussing risk and benefit. Veritassium made some mistakes, so here they are corrected so that you can participate effectively in these discussions.

Dec 20, 2025 • 1h 4min
TB Throwback: Gliblastoma and Cindy's Gift
This episode originally aired on December 18, 2021. Cindy Graham was diagnosed with glioblastoma in her late 40s. She fought the disease, and ultimately donated her tissues to research to study the nature of glioblastoma and identify potential vulnerabilities that could underlie a cure. This episode first features Dr. Shiela Singh, glioblastoma expert who has performed analysis of Cindy's cells in search of a cure. The second part is an interview with her husband, Dr. Thomas Graham. He speaks of the power of her gift, Cindy's legacy, and the hope that cures may come because of her contribution. The fund supports glioblastoma research and student scholarships to enhance the best research in search of a cure. You can support the fund at www.cindysgift.com

Dec 13, 2025 • 51min
TB Throwback: Dr. Avindra Nath and HERV-based Diseases
In today's throwback to 2022, Dr. Avindra Nath of the NIH reviews research efforts in proteins expressed from human endogenous retroviruses. It is a fascinating discussion of how genome relics may be contributing to insidious human disease.

Dec 6, 2025 • 38min
482 Dr. Maxine Thompson, Episode 117, Jan 18, 2015
This throwback episode to 2018 is an interview with plant breeding pioneer Dr. Maxine Thompson.

Nov 2, 2025 • 36min
A Biotech Probiotic to Enhance Fiber - Dr. Zack Abbott
Dr. Zack Abbott, CEO of ZBiotics and microbiologist, dives into the fascinating world of engineered probiotics designed to enhance gut health. They tackle the staggering fiber deficiency affecting 95% of Americans and explain how innovative probiotics can convert sugars into dietary fiber right in your gut. Zack shares insights on the science of levansucrase and its benefits for microbial diversity and gut integrity. With future possibilities for probiotics, they discuss addressing modern health challenges from dietary gaps to toxin detoxification.

29 snips
Oct 19, 2025 • 55min
Peer Review and Rigor in Controversial Science - Cam English, Dr. Liza Lockwood
Dr. Liza Lockwood, an expert on peer review and scientific integrity, joins Cameron English and Kevin Folta to discuss the frailties of academic publishing. They dive into the nuances of peer review, addressing concerns over low-quality studies and the pressure of 'publish or perish' culture. The trio explores how misinformation spreads and the challenges in correcting it, particularly during the COVID era. They also tackle the fallout from fraudulent research, emphasizing the critical need for transparency and accountability in science.

48 snips
Oct 11, 2025 • 50min
Everyone Else is Lying to You - Pandemic Disinformation - Dr. Jonathan Howard
Dr. Jonathan Howard, a neurologist and chief of neurology at Bellevue Hospital, delves into the troubling rise of pandemic disinformation. He shares insights from his frontline experiences treating COVID patients and discusses how pre-existing anti-vaccine sentiments infiltrated mainstream discourse. Howard identifies key figures influencing public health narratives and critiques the media's role in amplifying misinformation. He emphasizes the urgent need for the medical community to combat falsehoods and restore trust in science.

24 snips
Oct 5, 2025 • 42min
Targeting RNA with Therapeutics - Dr. Matthew Disney
Dr. Matthew Disney, an expert in small-molecule therapeutics at the UF Scripps Institute, dives into the revolutionary potential of RNA as a therapeutic target. He explores its pathogenic roles in diseases like ALS and myotonic dystrophy, and discusses innovative strategies to design small molecules that target structured RNA. Disney also highlights how RIBOTACs can recruit RNA-degrading enzymes, and shares insights on targeting viral genomes, including strategies for inhibiting SARS-CoV-2, showcasing the promising future of RNA therapeutics in combating various diseases.

37 snips
Sep 27, 2025 • 36min
Biotech Takes On the Screw Worm - Dr. Max Scott
Dr. Maxwell Scott, entomologist and expert in genetic pest management at North Carolina State University, delves into the menace of the screw worm, a parasitic insect affecting livestock. He shares insights on the historic success of the sterile insect technique in eradication efforts and discusses the current resurgence in North America. Fascinatingly, he explores innovative gene drive technologies being developed to manage screw worm populations while addressing public perception and regulatory challenges surrounding these genetic solutions.

22 snips
Sep 20, 2025 • 34min
Attacking Cancers through Neoantigens - Dr. Jackie Douglass
Dr. Jackie Douglas, a medical oncology fellow at Johns Hopkins specializing in neoantigens and cancer immunotherapy, dives into the promising world of personalized cancer treatments. She explains how neoantigens, unique to cancer cells, can be targeted for therapy. The discussion includes HLA alleles' roles, challenges like patient variability, and the exciting potential of mRNA vaccines in clinical trials. Douglas emphasizes the need for affordable therapies and shares insights on future advancements, all while maintaining a hopeful outlook for cancer patients.


